We are live on ! Find out more
ALEC icon

Alector

2.59 USD
+0.03
1.17%
At close Updated Nov 18, 4:00 PM EST
1 day
1.17%
5 days
-2.63%
1 month
32.82%
3 months
17.19%
6 months
22.17%
Year to date
69.28%
1 year
103.94%
5 years
-88.25%
10 years
-85.61%
 

About: Alector Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company advances a pipeline of product candidates including Nivisnebart (AL101/GSK4527226) for Alzheimer's disease, AL137 for Alzheimer's disease, AL050 for Parkinson's disease and Lewy body dementia, and AL064, an siRNA program targeting tau for Alzheimer's disease and other tauopathies, supported by its proprietary Alector Brain Carrier (ABC) platform designed to improve delivery of therapeutics across the blood-brain barrier.

Employees: 103

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 15.4%
Neutral 69.2%
Negative 15.4%
Negative
Zacks Investment Research
6 days ago
Are Medical Stocks Lagging Alector (ALEC) This Year?
Here is how Alector (ALEC) and CVS Health (CVS) have performed compared to their sector so far this year.
Are Medical Stocks Lagging Alector (ALEC) This Year?
Positive
Zacks Investment Research
7 days ago
Earnings Estimates Rising for Alector (ALEC): Will It Gain?
Alector (ALEC) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Earnings Estimates Rising for Alector (ALEC): Will It Gain?
Neutral
GlobeNewsWire
12 days ago
Alector Reports Third Quarter 2026 Financial Results and Provides Business Update
Advancing a pipeline built entirely on the Alector Brain Carrier (ABC) blood-brain barrier platform, spanning antibody, enzyme, and siRNA programs, with AL137, Alector's lead ABC-enabled anti-amyloid beta (Aβ) antibody program for Alzheimer's disease (AD), targeting first-in-human dosing in Australia no later than April 2027. Continued progress across AL164 (ABC-enabled Tau siRNA for AD and other tauopathies) and AL062 (ABC-enabled alpha-synuclein siRNA for Parkinson's disease (PD) and Lewy body dementia (LBD)), each targeting first-in-human studies in Q2 2028.
Alector Reports Third Quarter 2026 Financial Results and Provides Business Update
Negative
Zacks Investment Research
20 days ago
Will Alector (ALEC) Report Negative Q3 Earnings? What You Should Know
Alector (ALEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Alector (ALEC) Report Negative Q3 Earnings? What You Should Know
Neutral
GlobeNewsWire
1 month ago
Alector Announces Pricing of Underwritten Offering
SOUTH SAN FRANCISCO, Calif., Oct. 16, 2026 (GLOBE NEWSWIRE) -- Alector, Inc. (“Alector,” Nasdaq: ALEC), a biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced the pricing of an underwritten offering of common stock. Alector is selling 36,600,000 shares of common stock. The shares of common stock are being sold at an offering price of $2.05 per share, which represents a premium of approximately 7.3% over the closing price on October 15, 2026. The gross proceeds to Alector from this offering are expected to be $75,030,000.00 before deducting the underwriting discounts and commissions and other estimated offering expenses. All shares of common stock to be sold in the offering are being offered by Alector. The offering is expected to close on or about October 19, 2026, subject to the satisfaction of customary closing conditions.
Alector Announces Pricing of Underwritten Offering
Neutral
Seeking Alpha
1 month ago
Alector, Inc. (ALEC) Discusses Strategic Advances in Next Generation Neurodegeneration Therapies and Pipeline Developments Transcript
Alector, Inc. (ALEC) Discusses Strategic Advances in Next Generation Neurodegeneration Therapies and Pipeline Developments Transcript
Alector, Inc. (ALEC) Discusses Strategic Advances in Next Generation Neurodegeneration Therapies and Pipeline Developments Transcript
Neutral
MarketBeat
1 month ago
Alector Maps Brain-Delivery Pipeline for Alzheimer's, Parkinson's Therapies
Alector NASDAQ: ALEC outlined its strategy to advance brain-penetrant therapies for neurodegenerative diseases, highlighting an anti-amyloid beta antibody for Alzheimer's disease and two siRNA programs targeting tau and alpha-synuclein.
Alector Maps Brain-Delivery Pipeline for Alzheimer's, Parkinson's Therapies
Neutral
GlobeNewsWire
1 month ago
Alector to Host Virtual Research and Development Event Highlighting Wholly Owned Alector Brain Carrier (ABC)- Enabled Pipeline
Agenda to feature progress for AL137, its lead anti-amyloid beta antibody; AL164, its tau siRNA program; and AL062, its alpha-synuclein siRNA program
Alector to Host Virtual Research and Development Event Highlighting Wholly Owned Alector Brain Carrier (ABC)- Enabled Pipeline
Positive
Reuters
1 month ago
Alector soars as Roche licenses Parkinson's therapy for up to $1.27 billion
Swiss drugmaker Roche will pay up to $1.27 billion to license Alector's experimental treatment for ​Parkinson's disease, the US biotech said ‌on Monday, sending its shares surging 72% in premarket trading.
Alector soars as Roche licenses Parkinson's therapy for up to $1.27 billion
Neutral
GlobeNewsWire
1 month ago
Alector Enters Global License Agreement with Genentech for Brain Penetrant GCase Enzyme Replacement Therapy for Parkinson's Disease and Other Neurodegenerative Diseases
Alector grants Genentech exclusive rights to develop and commercialize AL050, an investigational GCase Enzyme Replacement Therapy (ERT) enabled by Alector Brain Carrier (ABC), Alector's proprietary blood-brain barrier delivery platform
Alector Enters Global License Agreement with Genentech for Brain Penetrant GCase Enzyme Replacement Therapy for Parkinson's Disease and Other Neurodegenerative Diseases
Price charts implemented using Lightweight Charts™